Panion & BF Biotech Inc (寶齡富錦), which manufactures pharmaceuticals, cosmetics and consumer healthcare products, said yesterday that it expects its new drug for treating kidney disease to acquire a permit in Taiwan in three months.
The company’s optimism came after the Food and Drug Administration (FDA) on Feb. 19 rejected the company’s application to license new drug Nephoxil.
The FDA has agreed to conduct another review if the company is able to supplement its data within three months.
“The main concern for the administration is that the company cannot use data compiled by our US partner Keryx Biopharmaceuticals Inc because it used tablets for its clinical trials, while we used capsules,” president Michael Chiang (江宗明) told an investors’ conference in Taipei yesterday.
Chiang said the company has fully cooperated with the FDA to provide the necessary data for further review.
Nephoxil gained approval in Japan on Jan. 17 and has been under review for a new drug application in the US since August last year and in Europe since Monday last week, said Raymond Chuang (莊瑞元), a senior manager at the company.
The company has licensed the drug to US-based Keryx Biopharmaceuticals and Japan-based Torii Pharmaceutical Co, and it will receive milestone payments and single-digit percentage royalty payments on sales of the drug in those two countries, Chuang said.
The two companies will also pay a manufacturing fee for the active pharmaceutical ingredients to Panion & BF Biotech, he added.
However, the company has to pay 33.4 percent of the milestone payments and 50 percent of the royalties it receives in the US, Japan and in five European nations to the person who invented the drug, Chuang said.
Chuang said Nephoxil is currently the only drug in the world that can reduce both high serum phosphate level and anemia resulting from kidney problems, which will allow the drug to grab a large market share and sell at a higher price.
The combined sales of Sevelamer and Lanthanum, which are most commonly used together to treat high serum phosphate levels caused by kidney problems, were US$1.2 billion worldwide in 2012, Chuang said, citing the financial reports of Sanofi SA, which sells Sevelamer, and Shire PLC, which sells Lanthanum.
Chuang said patents for the drug last until 2024 at the earliest.
Last year, the company posted revenue of NT$847.78 million (US$27.93 million), up 26.76 percent from NT$668.79 million the previous year, according to a company filing to the Taiwan Stock Exchange.
In the first half of last year, the company swung into the black with a profit of NT$3.1 million, or earnings per share of NT$0.09, after it reported losses the previous three years because of high drug development costs, it said.
Panion & BF Biotech financial and accounting division vice president Eric Wang (王烽任) said the company’s profitability last year was “satisfactory.”
Panion & BF Biotech shares rose 1.58 percent to close at NT$393.5 yesterday on the Emerging Stock Market, outperforming the over-the-counter benchmark index, which was up 0.48 percent.
WASHINGTON’S INCENTIVES: The CHIPS Act set aside US$39 billion in direct grants to persuade the world’s top semiconductor companies to make chips on US soil The US plans to award more than US$6 billion to Samsung Electronics Co, helping the chipmaker expand beyond a project in Texas it has already announced, people familiar with the matter said. The money from the 2022 CHIPS and Science Act would be one of several major awards that the US Department of Commerce is expected to announce in the coming weeks, including a grant of more than US$5 billion to Samsung’s rival, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), people familiar with the plans said. The people spoke on condition of anonymity in advance of the official announcements. The federal funding for
HIGH DEMAND: The firm has strong capabilities of providing key components including liquid cooling technology needed for AI servers, chairman Young Liu said Hon Hai Precision Industry Co (鴻海精密) yesterday revised its revenue outlook for this year to “significant” growth from a “neutral” view forecast five months ago, due to strong demand for artificial intelligence (AI) servers from cloud service providers. Hon Hai, a major assembler of iPhones that is also known as Foxconn, expects AI server revenues to soar more than 40 percent annually this year, chairman Young Liu (劉揚偉) told investors. The robust growth would uplift revenue contribution from AI servers to 40 percent of the company’s overall server revenue this year, from 30 percent last year, Liu said. In the three-year period
LONG HAUL: Largan Energy Materials’ TNO-based lithium-ion batteries are expected to charge in five minutes and last about 20 years, far surpassing conventional technology Largan Precision Co (大立光) has formed a joint venture with the Industrial Technology Research Institute (ITRI, 工研院) to produce fast-charging, long-life lithium-ion batteries for electric vehicles, mobile electronics and electric storage units, the camera lens supplier for Apple Inc’s iPhones said yesterday. Largan Energy Materials Co (萬溢能源材料), established in January, is developing high-energy, fast-charging, long-life lithium-ion batteries using titanium niobium oxide (TNO) anodes, it said. TNO-based batteries can be fully charged in five minutes and have a lifespan of 20 years, a major advantage over the two to four hours of charging time needed for conventional graphite-anode-based batteries, Largan said in a
Taiwan is one of the first countries to benefit from the artificial intelligence (AI) boom, but because that is largely down to a single company it also represents a risk, former Google Taiwan managing director Chien Lee-feng (簡立峰) said at an AI forum in Taipei yesterday. Speaking at the forum on how generative AI can generate possibilities for all walks of life, Chien said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) — currently among the world’s 10 most-valuable companies due to continued optimism about AI — ensures Taiwan is one of the economies to benefit most from AI. “This is because AI is